-+ 0.00%
-+ 0.00%
-+ 0.00%

Nexentis unit MitoCareX Bio expands SLC transporter analysis for drug discovery

PUBT·07/07/2026 12:25:31
Listen to the news
Nexentis unit MitoCareX Bio expands SLC transporter analysis for drug discovery
  • Nexentis unit MitoCareX Bio completed a broad analysis of SLC transport proteins to expand targets for small-molecule drug discovery.
  • Work extends MITOLINE sequence alignment used to prepare mitochondrial SLC25 carriers for structural modeling in oncology, inflammatory metabolic diseases.
  • Analysis flagged additional non-SLC25 transporters as potentially compatible with MITOLINE modeling rules, widening the addressable target set.
  • MitoCareX entered an international AI drug discovery initiative with Boltz to combine MITOLINE with foundation models for structure, binding, molecule design.
  • Program aims to speed identification and progression of SLC-focused drug candidates, supporting pipeline expansion in oncology, metabolic disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070825PRIMZONEFULLFEED9758113) on July 07, 2026, and is solely responsible for the information contained therein.